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Adjuvant systemic therapy was introduced in the Netherlands as a breast cancer treatment in the early 1980s. In this paper, we
describe the trends in the usage of adjuvant systemic treatment in the period 1975–1997 in the Netherlands. The main aim of our
study was to assess the effects of adjuvant tamoxifen and polychemotherapy on breast cancer mortality, compared to the effects of
the mammography screening programme. The computer simulation model MIcrosimulation SCreening ANalysis, which simulates
demography, natural history of breast cancer and screening effects, was used to estimate the effects. Use of adjuvant therapy
increased over time, but since 1990 it remained rather stable. Nowadays, adjuvant therapy is given to 88% of node-positive patients
aged 50–69 years, while less than 10% of node-negative patients receive any kind of adjuvant treatment. Adjuvant treatment is given
independent of the mode of detection (adjusted by nodal status and size). We predict that the reduction in breast cancer mortality
due to adjuvant therapy is 7% in women aged 55–74 years, while the reduction due to screening, which was first implemented in
women aged 50–69 years in 1990–97, will be 28–30% in 2007. In conclusion, although adjuvant systemic therapy can reduce breast
cancer mortality rates, it is anticipated to be less than the mortality reduction caused by mammography screening.
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The use of adjuvant polychemotherapy and hormonal therapy for
early breast cancer has strongly increased over the last two
decades. This often happened subsequent to new data from the
worldwide overview analyses of randomised clinical trials asses-
sing the effects of adjuvant therapy, showing significant benefits in
disease-free and overall survival (EBCTCG, 1992, 1998a,b).
In 2000, the Dutch National Breast Cancer Platform (NABON)
and the Dutch Society for Medical Oncology (NVMO) developed a
consensus guideline for adjuvant systemic therapy (Bontenbal et al,
2000). It recommended tamoxifen use for patients with node-
positive tumours and a positive oestrogen and/or progesterone
receptor status. Chemotherapy was recommended for all node-
positive tumours in premenopausal women and in postmenopau-
sal women under age 70, with a negative hormonal receptor status.
For node-negative tumours, the recommendation of adjuvant
therapy depends on the tumour size, differentiation grade and
mitotic activity index. Before the introduction of this new
guideline, tamoxifen was mainly recommended for postmenopau-
sal women with node-positive tumours and chemotherapy for
premenopausal women with node-positive tumours.
Only few data are available on the use of adjuvant therapy in
different countries, including the Netherlands, over the last two
decades. More information about its use and effects would be
needed in order to explain what part of the recent mortality
reduction in breast cancer patients in the Netherlands may be
caused by changes in adjuvant therapy and what part can be
contributed to the Dutch breast cancer screening programme (Otto
et al, 2003).
The main objective of this study is to assess the potential effects
of adjuvant polychemotherapy and adjuvant tamoxifen on breast
cancer mortality in the Netherlands using the microsimulation
model MIcrosimulation SCreening ANalysis (MISCAN) (De
Koning et al, 1995). This model simulates the future demographic
characteristics of the Dutch population, the natural history of
breast cancer and screening effects. We assess in this paper the
trends in the usage of adjuvant polychemotherapy and adjuvant
tamoxifen for the treatment of breast cancer in the Netherlands
from 1975 until 1997, and estimate its potential impact on
mortality.
MATERIALS AND METHODS
Data sources
The Dutch national biannual breast cancer screening programme
started around 1990 and covered in 1997 all women aged 50–69
years. Data from all nine regions, carrying out the screening
programme, have been collected and analysed since 1990 by the
National Evaluation Team for Breast cancer screening (NETB), that
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invitations and examinations, breast cancers diagnosed, interval
cancers and breast cancer therapy (Fracheboud et al, 2001).
Detailed data on the use of adjuvant systemic therapy were
obtained from the NETB and the Eindhoven Cancer Registry
(ECR).
The Southeast Netherlands, with a population of almost one
million inhabitants (6% of the Dutch population), is covered by the
population-based regional Eindhoven Cancer Registry, which
collected data from pathology reports and clinical records on all
cancer patients since 1955 according to international guidelines
(Voogd et al, 1994). It is part of the Dutch Cancer Registry since
1989. We used a data set on adjuvant therapy from 1975 until 1997.
Patients were staged according to the TNM system.
Description of the MISCAN model
The computer simulation package MISCAN was used to assess the
effects of adjuvant systemic therapy on breast cancer mortality. A
full description of the MISCAN model has been published before
(van Oortmarssen et al, 1990; De Koning et al, 1995). In brief, the
model first simulates individual life histories for women in the
absence of screening and then assesses how these histories would
change as a consequence of a screening program. The natural
history is modelled as a progression from no breast cancer through
preclinical disease to clinical disease.
The different disease states are: no breast cancer, five preclinical
disease states, namely Ductal Carcinoma In Situ (DCIS) and four
invasive preclinical states according to tumour size (o0.5, 0.6–1.0,
1.1–2.0 and 42.0cm). From a given preclinical state, a cancer may
be detected by screening, or become clinically apparent or, if
undiagnosed, progress to the next preclinical state. Parameters of
the preclinical phase such as transition probabilities between
states, mean durations and sensitivities of the screening test were
based on data from the Dutch screening programme and the pilot
studies in Utrecht and Nijmegen (van Oortmarssen et al, 1990;
LETB, 1994). After a diagnosis of breast cancer, the survival period
depends on the disease state and age at time of diagnosis. Survival
parameters have been estimated from the pilot studies. In the
breast cancer model, women with screen-detected cancers can have
a reduced risk of dying of breast cancer depending on the detected
cancer size. Stage-specific cure rates of screen-detected cancers
have been estimated from the published data of the Swedish trials
(Nystro ¨m et al, 1993; De Koning et al, 1995). The model output
includes the number of screen-detected and clinically detected
cancers and their stage distributions, the clinical age-specific
breast cancer incidence by stage and the age-specific breast cancer
mortality, all for both the situation with and without screening.
The programme has been used extensively to analyse screening
in various settings (van Ineveld et al, 1993; Paci et al, 1995; van den
Akker-van Marle et al, 1997) and to predict mortality trends (van
den Akker-van Marle et al, 1999).
Adaptations in model
For the present purpose, we extended the breast cancer model with
lymph node status: during tumour growth, breast cancer can
Table 1 Hazard ratios and mean proportions of women using adjuvant therapy in 1990–97 in different MISCAN models
Hazard ratio
Proportion of women using adjuvant therapy (proportion of
total number of women with breast cancer)
N  N+ N  N+
Treatment and age
Tamoxifen for 2 years, age o50 0.89
a 0.81
a 0.0
b (16.0) 0.1
b (13.0)
Tamoxifen for 2 years, age 50–69 0.89
a 0.81
a 0.065
b (32.0) 0.78
b (19.0)
Tamoxifen for 2 years, age 70+ 0.89
a 0.81
a 0.065
b (12.0) 0.85
b (8.0)
Chemotherapy, age o50 0.73
a 0.73
a 0.02
b (16.0) 0.70
b (13.0)
Chemotherapy, age 50–69 0.89* 0.89
a 0.01
b (32.0) 0.12
b (19.0)
Chemotherapy, age 70+ 1.0 1.0 0.0
b (12.0) 0.01
b (8.0)
aData were obtained from the 1998 Early Breast Cancer Trialists’ Collaborative Group meta-analysis of clinical trials (EBCTCG, 1998a,b).
bData were obtained from the NETB
and the Eindhoven Cancer Registry.
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Figure 1 (A–C) Trends in the usage of tamoxifen and chemotherapy in
1975–97 in the Southeast region (ECR) and all regions of the Netherlands
(NE), subdivided by age (source: Eindhoven Cancer Registry and NETB).
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Transition probabilities were estimated from data of the national
screening programme (LETB, 1994). Tumour size and lymph node
status-specific survival were estimated from the Utrecht pilot study
of screening (Collette et al, 1992). This pilot study was conducted
mainly before the introduction of adjuvant therapy, and therefore
is a good starting point to estimate the contribution of adjuvant
therapy to observed mortality trends. The extended model
reproduced the incidence, stage distribution and mortality from
breast cancer in the Netherlands satisfactorily.
The benefit of adjuvant therapy in reducing breast cancer
mortality was included in the model using the published
proportional reductions in annual odds of death from adjuvant
tamoxifen and polychemotherapy from the 1998 Early Breast
Cancer Trialists’ Collaborative Group (EBCTCG) meta-analysis of
clinical trials (EBCTCG, 1998a,b). We used these hazard ratios to
predict the effects of tamoxifen and polychemotherapy on breast
cancer mortality (Table 1).
Analysis model
We established three different models, the first one without the
effects of adjuvant therapy (which consists of the MISCAN model
including nodal status), the second including effects of chemother-
apy and the third model including the effects of tamoxifen. We
predicted breast cancer mortality rates per 100000 person-years,
using the number of deaths from breast cancer as the numerator
and the female population as the denominator. We compared the
mortality rates for three different age groups, 45–54, 55–64 and
65–74 years. Here, age is specified as age at death. MISCAN
predicts mortality rates for the period 1986–2015 for situations
with and without adjuvant therapy (chemotherapy and tamoxifen
together), and in which a screening programme does and does not
exist.
In order to calculate the mortality rates for women using
adjuvant therapy, we took weighted averages of the number of
breast cancer deaths and life-years in each of the three models.
Subsequently, we divided the number of deaths by life-years lived
to calculate the mortality rates. The weights are the mean
proportions of women by age, who received tamoxifen or
polychemotherapy or none in 1990–97 (Table 1). Although
adjuvant therapy was already introduced at a small scale in the
early 1980s, we used data of the period 1990–97, because the use of
adjuvant therapy remained rather stable since 1990 and we
assumed a constant use of adjuvant therapy.
RESULTS
Figure 1A–C illustrates the trends in the use of hormonal therapy
and chemotherapy for women diagnosed with breast cancer at age
o50, 50–69 and 70þ in the years 1975–97. In the age group 50–
69, the data from the Southeast Netherlands and the Netherlands
are comparable in the overlapping period 1990–97. In the age
group 470, the Eindhoven Cancer Registry reported a somewhat
higher use of both tamoxifen and chemotherapy than the
Netherlands as a whole in the period 1990–97. The proportion
of patients receiving adjuvant chemotherapy increased in 1980–84,
especially in the age group o50, but also in the age group 50–69,
and thereafter decreased in 1985–89. In the latter period, there was
a large increase in the treatment with tamoxifen for all age groups.
In 1990–97, the use of adjuvant tamoxifen and chemotherapy
remained rather stable in the Netherlands.
Table 2 summarises the use of adjuvant therapy by detection
status and nodal status for women aged 50–69 in 1990–97.
Adjuvant chemotherapy was mainly administered to node-positive
premenopausal patients and adjuvant tamoxifen to node-positive
postmenopausal patients in 1975–97. The use of adjuvant systemic
therapy did not depend on screen status. In both screened and not-
screened women with node-positive tumours, 88% received
adjuvant therapy. In 1990–97, 5.2% of the patients with node-
negative screen-detected cancers and 9.8% with node-negative
clinically detected cancers received adjuvant therapy (P¼0.219).
Table 2 Adjuvant therapy by screening status and nodal status for age group 50–69 years in 1990–1997
Period N  (N) H (%) C (%) H+C (%) All (%) N+ (N) H (%) C (%) H+C (%) All (%) All tumours (N) H (%) C (%) H+C (%) All (%)
Screen-detected
1990 180 2.2 0.0 0.0 2.2 64 75.0 3.1 0.0 78.1 244 21.3 0.8 0.0 22.1
1991 422 6.6 0.2 0.0 6.8 170 62.9 10.0 7.1 80.0 592 22.8 3.0 2.0 27.9
1992 798 8.3 0.0 0.0 8.3 307 73.9 6.8 2.9 83.6 1105 26.5 1.9 0.8 29.2
1993 985 7.4 0.1 0.0 7.5 343 74.9 4.4 4.4 83.7 1328 24.8 1.2 1.1 27.2
1994 1160 2.8 0.1 0.0 2.9 376 77.4 5.3 2.4 85.1 1536 21.1 1.4 0.6 23.0
1995 1146 3.6 0.4 0.1 4.1 415 79.3 7.2 2.9 89.4 1561 23.7 2.2 0.8 26.8
1996 1293 3.8 0.3 0.0 4.1 442 75.6 9.7 3.9 89.2 1735 22.1 2.7 1.0 25.8
1997 1300 4.9 0.9 0.1 5.9 448 78.4 16.1 3.6 98.1 1748 23.7 4.7 1.0 29.4
1990–97 7284 4.9 0.3 0.0 5.2 2565 75.8 8.6 3.5 87.9 9849 23.4 2.5 0.9 26.8
1990–97 T1N0 4.6 0.2 0.0 4.8 T1N1 74.9 8.7 3.3 86.9
T2+N0 9.3 1.2 0.2 10.7 T2+N1 76.3 8.3 3.7 88.3
Not screen-detected
1990 1062 8.2 0.9 0.7 9.8 792 72.7 5.6 1.9 80.2 1854 35.8 2.9 1.2 39.8
1991 1171 11.2 1.0 0.6 12.8 853 76.9 11.3 1.3 89.5 2024 38.9 5.3 0.9 45.1
1992 1227 10.3 1.6 1.0 12.9 901 75.0 7.1 2.8 84.9 2128 37.7 3.9 1.7 43.4
1993 1194 9.1 1.8 0.9 11.8 850 73.9 9.8 4.0 87.7 2044 36.1 5.1 2.2 43.3
1994 1343 5.1 1.9 1.4 8.4 1027 72.4 12.1 3.9 88.4 2370 34.3 6.3 2.5 43.0
1995 1088 4.7 0.8 0.3 5.8 836 76.0 11.1 3.2 90.3 1924 35.7 5.3 1.6 42.5
1996 1040 6.1 0.7 0.0 6.8 757 71.5 13.2 4.8 89.5 1797 33.6 6.0 2.0 41.6
1997 1042 7.4 1.7 0.6 9.7 758 70.6 17.7 6.3 94.6 1800 34.0 8.4 3.0 45.4
1990–97 9167 7.8 1.3 0.7 9.8 6774 73.7 10.9 3.5 88.1 15941 35.8 5.4 1.9 43.1
1990–97 T1N0 6.9 1.1 0.8 8.8 T1N1 74.9 10.4 2.9 88.2
T2+N0 12.2 2.2 0.8 15.2 T2+N1 73.5 11.6 3.9 89.0
Source: NETB. H¼hormonal therapy, C¼chemotherapy.
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lIn node-positive patients, adjuvant therapy did not depend on
tumour size, whereas in node-negative patients use of adjuvant
tamoxifen increased as tumour size increased.
Figure 2A–C illustrates breast cancer mortality rates predicted
by MISCAN, both for the situation with and without screening and
adjuvant therapy. In women aged 55–74, the mortality reduction
due to adjuvant therapy is 7% in the situation without screening
and 6% in the situation with screening. At 10 years after the
screening programme is fully implemented (2007), and the
maximum screening effect is reached, the predicted breast cancer
mortality reduction due to screening would be 28–30%. Of the
estimated total breast cancer mortality reduction of 34% in women
aged 55–74, approximately 80% would then be explained by
screening, whereas 20% would contribute to the use of adjuvant
therapy. The predicted mortality rates in unscreened women aged
45–54 in the situation with and without adjuvant therapy use are
47 and 53 per 100000 person-years, respectively. Thus, the
mortality reduction due to adjuvant therapy would be 11%. The
mortality reduction due to screening, which was first implemented
in women aged 50–69, would be 5%. Thus, in the age group 45–
54, less than 30% of the total breast cancer mortality reduction
could be explained by screening, whereas 70% could be attributed
to adjuvant therapy use. We assumed tamoxifen treatment for 2
years, because this was the common treatment in the Netherlands.
We also predicted mortality rates for tamoxifen treatment for 5
years (data not shown), and found that the breast cancer mortality
reduction due to adjuvant therapy would then be 10% in the age
group 55–74.
DISCUSSION
Our study suggests that the breast cancer mortality reduction
caused by present-day practice of adjuvant tamoxifen and
chemotherapy is 7%. This effect is about four times smaller than
the reduction caused by breast cancer screening, estimated to
amount 28–30% in 2007. This indicates that the screening
programme in the Netherlands has contributed most to the recent
reduction in breast cancer mortality in women aged 50–69,
although adjuvant therapy could also have played an important
role, particularly in the early 1990s. As most of the women who
died at age 45–54 have not participated in the screening
programme, the mortality reduction due to adjuvant treatment
in this age group must be larger than due to screening. Tamoxifen
contributes most to the mortality reduction from adjuvant therapy
in women aged 55–74, because it is prescribed to mainly
postmenopausal women. In this age group, less than 10% of
node-positive women and less than 1% of node-negative women
receive chemotherapy, so the overall effect of chemotherapy on
mortality is very small. The effect of chemotherapy is particularly
seen in the age group o50.
Adjuvant systemic therapy was introduced and used on a large
scale before the implementation of the screening programme.
There has been little change in the use of adjuvant therapy since
1990 and the maximum mortality reduction by adjuvant therapy
was expected to appear already in the first years after its maximum
use (in 1990–94). In the case of screening, a significant mortality
reduction is expected some years after 1997 (Otto et al, 2003), the
year in which the screening programme was fully implemented.
Therefore, the mortality-lowering effect of the increased use of
adjuvant treatment in the 1980s is expected to occur before the
effect of the screening programme.
S i n c ew ea d j u s t e ds u r v i v a la f t e rc l i n i c a ld i a g n o s i si nM I S C A N ,t h e
use and effects of adjuvant therapy are the same for clinically
detected cancers and screen-detected cancers, despite earlier detec-
tion and improvement in prognosis of the latter. As screening leads
to the detection of smaller tumour sizes and these tumours are less
likely to receive adjuvant therapy, it can be argued that this will lead
to a decline in the use of adjuvant therapy in screen-detected cancers.
In a previous study in England and Wales, Blanks et al (2000)
estimated that screening contributed one-third, and other factors
(including improved treatment with adjuvant systemic therapy)
two-thirds to the total breast cancer mortality reduction. They
argued that the estimated mortality reduction from screening may
be lower than the mortality reduction predicted by MISCAN (van
den Akker-van Marle et al, 1999) because of the lower sensitivity of
the UK screening programme in the early years of screening. It has
been suggested that, in the UK, there were substantial changes in
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Figure 2 Breast cancer mortality rates predicted by MISCAN for effects
of screening and adjuvant therapy (chemotherapy and tamoxifen). (A) Age
group 45–54 (assumed first screening attendance rate of 79% in the age
group 50–54). (B) Age group 55–64 (assumed first screening attendance
rate of 76–79% in the age group 55–64). (C) Age group 65–74 (assumed
first screening attendance rate of 72–74% in the age group 65–69).
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1980s, compared to the Netherlands. Moreover, it is likely
that primary treatment as such changed considerably in the
UK, whereas in the Netherlands primary treatment including
radiation treatment was already practised according to guidelines
(Bontenbal et al, 2000).
Approximately 70% of all breast cancer deaths are in patients
with involved axillary nodes at diagnosis. Using this percentage
and the proportions of women receiving tamoxifen or polyche-
motherapy and the odds reductions in mortality from the EBCTCG
trial (Table 1), we calculated that the expected mortality reduction
due to adjuvant treatment in women aged 50–69 should
be approximately (0.7 0.78 0.19)þ(0.3 0.065 0.11)þ(0.7 
0.12 0.11)þ(0.3 0.01 0.11)¼11.5%. However, MISCAN pre-
dicted that the mean mortality reduction from adjuvant therapy
was 7.3% in this age group. For the age group 45–49, we calculated
a mortality reduction from adjuvant therapy of 14.6%, whereas
MISCAN predicted a mortality reduction of 12.4%. The explana-
tion for this lower than expected mortality reduction, predicted by
MISCAN, is as follows. The effect of adjuvant therapy on survival
after clinical diagnosis was modelled assuming a constant ratio
between the hazards (at time t since diagnosis) of dying of breast
cancer in the treated and untreated groups. A hazard ratio (r)o f
0.8, however, does not translate in a mortality ratio of 0.8. A
numerical example: take r¼0.8 and take a 10-years survival
without adjuvant therapy of 0.4. Then, the 10-year survival with
adjuvant therapy equals (0.4)^0.8¼0.48 and the mortality with
adjuvant therapy 0.52 and without therapy 0.6. The mortality ratio
can be calculated as 0.52/0.6¼0.87. A hazard ratio of 0.8 thus leads
to a mortality ratio of 0.87, so the mortality reduction will be 13%
(in stead of 20%). The smaller the tumour size and thus the better
the survival, the smaller the difference between the hazard ratio
and the mortality ratio.
Several factors may have led to an underestimation of the effect
of adjuvant systemic therapy. Firstly, the recent introduction of
new guidelines in 2000 for treatment of node-negative cancers will
lead to an increase in the use of adjuvant therapy in the next few
years. Therefore, our predicted mortality reductions could be an
underestimation of the actual effect of adjuvant therapy in the
future. Secondly, since 1990 there is a shift in the Netherlands from
short-term (1–2 years) to long-term use (5 years) of tamoxifen.
Furthermore, the application of adjuvant therapy has improved.
Therefore, it could be argued that the expected mortality reduction
from adjuvant therapy will be somewhat higher than we predicted.
There was a four-fold increase in the use of tamoxifen in the
period 1985–89. This increase can be explained by the publication
in 1988 of an overview of several trials on tamoxifen, which
showed a significant mortality reduction if tamoxifen was used in
postmenopausal node-positive patients (EBCTCG, 1988). More-
over, this drug was prescribed increasingly to women with a
negative hormonal receptor status. A study in the Southeast
Netherlands showed an increase in the use of tamoxifen for node-
positive postmenopausal patients with oestrogen receptor-negative
tumours from 0% in 1986–87 to 53% in 1990–91 (Voogd et al,
1994). In the case of oestrogen receptor-positive tumours,
tamoxifen use also increased. Several trials have investigated the
relation between hormonal receptor status and the effect of
tamoxifen, but different results have been published. Although the
1985 NIH consensus conference concluded that tamoxifen should
be given only to women with ER-positive tumours, the 1992
EBCTCG overview showed significant mortality reductions for
women older than 50, even for those with tumours classified as
oestrogen poor (EBCTCG, 1992). The conclusion from the
EBCTCG overview in 1998 was that all postmenopausal women
with a positive hormonal receptor status should receive hormonal
therapy and that there was no clear benefit from tamoxifen in
women with oestrogen and progesterone receptor-negative tu-
mours (EBCTCG, 1998b). This has influenced the new guidelines,
which do not recommend tamoxifen for hormonal receptor-
negative tumours.
In conclusion, the use of adjuvant therapy strongly increased in
the period 1975–97. It contributed considerably to the breast
cancer mortality reduction, observed in several countries. Never-
theless, based on estimated calculations, it is good to realise that
screening has an (additional) effect that in the Netherlands may be
three to four times as large.
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Appendix A
Data regarding the trends in usage of adjuvant therapy are shown
in Table A1.
Table A1 Trends in the usage of adjuvant therapy by age and nodal status in the Netherlands
Breast
cancers
(N)
Breast
cancers (N) C (%) H (%)
Breast
cancers (N) C (%) H (%)
Breast
cancers (N) C (%) H (%)
Period Stage All ages Ageo50 Age o50 Age o50 Age 50–69 Age 50–69 Age 50–69 Age 70+ Age 70+ Age 70+
ECR
1975–80 N  657 219 5.5 0.0 305 4.3 2.0 133 1.5 0.0
1980–84 N  886 292 1.7 0.0 380 2.1 0.3 214 0.5 2.3
1985–89 N  1479 478 1.7 0.2 690 0.6 3.0 311 0.0 7.4
1990–94 N  2829 748 2.3 0.4 1,522 0.3 3.0 559 0.0 7.2
1995–97 N  1898 486 1.9 0.4 1,027 0.5 1.3 385 0.0 5.7
1975–80 N+ 617 192 26.6 6.8 318 14.8 7.6 107 4.7 2.8
1980–84 N+ 741 236 58.1 2.5 353 22.4 12.5 152 5.3 9.9
1985–89 N+ 1165 381 53.0 7.6 582 11.9 51.2 202 0.5 59.4
1990–94 N+ 1972 646 60.2 7.7 919 10.8 71.0 407 1.7 80.8
1995–97 N+ 1220 386 77.7 11.7 562 12.3 77.9 272 0.7 92.7
1975–80 All 1631 492 15.7 3.3 777 11.1 4.1 362 6.1 1.1
1980–84 All 1890 574 27.7 1.9 818 14.3 6.6 498 4.0 10.2
1985–89 All 3157 916 25.0 4.5 1430 7.5 27.4 811 0.7 43.5
1990–94 All 5580 1488 30.6 5.0 2665 6.4 29.3 1427 1.4 49.8
1995–97 All 3608 927 36.4 5.7 1751 5.9 32.0 930 1.4 48.9
NE
1990 All 6093 1692 28.5 3.9 2733 3.4 32.7 1668 1.1 38.3
1991 All 6520 1828 34.0 3.7 3085 4.7 34.9 1607 1.3 40.3
1992 All 7021 1886 32.9 3.8 3385 3.1 34.5 1750 0.2 42.1
1993 All 7325 1962 33.5 4.6 3583 3.1 31.5 1780 0.4 41.9
1994 All 8973 2436 32.9 4.5 4136 3.9 29.5 2365 0.3 39.6
1995 All 7844 2169 34.1 3.9 3669 4.0 30.4 2006 0.2 39.8
1996 All 8190 2347 34.1 3.5 3720 4.3 28.3 2123 0.3 42.8
1997 All 8275 2316 35.8 3.7 3880 6.4 27.5 2079 0.4 42.1
1990–94 All 35932 9804 32.5 4.1 16922 3.7 32.4 9170 0.6 40.4
1995–97 All 24309 6832 34.7 3.7 11269 4.9 28.7 6208 0.3 41.6
Source: NETB and Eindhoven Cancer Registry. C¼chemotherapy, H¼hormonal therapy.
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